Bell Potter Reaffirms Their Buy Rating on Cyclopharm Limited (CYC)

Business Insider

2 days ago

In a report released today, John Hester from Bell Potter maintained a Buy rating on Cyclopharm Limited (CYC – Research Report), with a price target of A$2.20. The company's shares closed today at A$1.14.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Hester is a 4-star analyst with an average return of 7.1% and a 50.56% success rate. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Cyclopharm Limited.
The company has a one-year high of A$2.50 and a one-year low of A$1.03. Currently, Cyclopharm Limited has an average volume of 92.52K.